This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 55 participants
Primary Purpose: Treatment
Official Title: Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection
Estimated Study Start Date: April 2020
Estimated Study Completion Date: April 2021
Donor Eligibility Criteria*:
Recipient Eligibility Criteria:*:
Recipients age >18 years old, are assigned to one of two clinical tracks, track 2 or 3, based on COVID-19 disease severity.
- Hospitalized, moderate symptoms requiring medical care for COVID-19 infection
- Symptoms may include fever, dyspnea, dehydration among others
- Requiring mechanical ventilation for the care of COVID-19 infection
Recipient exclusion Criteria*:
* Additional criteria apply. Please speak with the study team for further information.
Experimental: Convalescent Plasma
Fresh plasma will be infused one time to hospitalized patients with COVID-19 infection
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.